Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

Cost Effectiveness Working Group ERS 2017

111 vues

Publié le

Cost Effectiveness Working Group ERS 2017

Publié dans : Santé & Médecine
  • Soyez le premier à commenter

Cost Effectiveness Working Group ERS 2017

  1. 1. ERS 2017 Milan, 9th September 2017 Cost Effectiveness Working Group Meeting
  2. 2. Agenda • Attendees and core members • Working group goals • Priorities for future research o Review potential studies o Other research ideas o Funding opportunities o Setting priorities • Additional items
  3. 3. Attendees • J van Boven (chair) • A Azuma • A Cruz • U Seppala • G Crater • P Rivera Ortega
  4. 4. WG core members • Lead: Associate prof. dr. Jonathan D Campbell (Denver, USA) • Assistant prof. dr. Job FM van Boven (Groningen, Netherlands) • Assistant prof. dr. Mohsen Sadatsafavi (Vancouver, Canada) • Assistant prof. dr. R Brett McQueen (Denver, USA)
  5. 5. Goals of cost-effectiveness working group • Perform real-life and modelling studies on the cost-effectiveness of respiratory treatments • Raise awareness on the importance of cost-effectiveness and identify gaps in currect research • Provide input for clinical studies with an economic component • Provide workshops/education on health economic issues in respiratory medicine inside and outside REG
  6. 6. Core Member Selected Recent Publications • Asthma CEA o Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Annals of Allergy, Asthma & Immunology. 2016 Dec 3. S1081-1206(16):31267-4. o Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? Journal of Asthma. 2017 Jan 2. 54(1):17-23. o Price DB, van Boven JF, Law LM, Cifra A, McQueen RB. Cost comparison of asthma treatment in 12- week study: caution about matching and short follow-up. Multidiscip Respir Med 2016; 11:39 o Kim CH, Dilokthornsakul P, Campbell JD, van Boven JF. Asthma cost-effectiveness analyses: Are we using the recommended outcomes in estimating value? JACI In Practice 2017 in-press. • COPD CEA o Van Boven JF, McQueen RB, Price DB. COPD case finding: effective, but also cost-effective? Lancet Respir Med 2016; 4(10):e49 o Van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in The Netherlands. Int J COPD 2016; 11:2191-2201 o JF van Boven. Costly comorbidities of COPD: the ignored side of the coin? European Respiratory Journal 2017; 49(7):1700917
  7. 7. Gaps identified through review • van der Schans S, Goossens LM, Boland MR, Kocks JW, Postma MJ, van Boven JF, Rutten-van Mölken MP. Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. Pharmacoeconomics. 2017 Jan;35(1):43-63 • CH Kim, P Dilokthornsakul, JD Campbell, JF van Boven. Asthma cost-effectiveness analyses: Are we using the recommended outcomes in estimating value? Journal of Allergy & Clinical Immunology: In Practice 2017 • Both reviews identified the need for: - Incorporation of side-effects (local/systemic), comorbidities and adherence - Standardization of costs and (respiratory) outcomes - Better reflection of treatment patterns in real-life
  8. 8. Asthma Gaps
  9. 9. COPD Gaps • Efficacy versus Effectiveness and how this translates to Cost- Effectiveness o Exacerbations: should be standardized; severe: hospitalization, non-severe: ED or GP visit. o Adherence o Populations o Comorbidities o Long-term side effects and their clinical and economic consequences • Utility: standardize estimates for GOLD stages and exacerbations. o Outcomes: Ideally both the EQ-5D and a COPD specific HRQoL should be used. • Perspective: payer versus societal o Indirect costs
  10. 10. Prioritizing Research Topics/research areas for consideration 1 Indirect Costs of Asthma, COPD, and Overlap Syndrome (ACOS) 2 Quality of life measurement and preference scores in real-life asthma and COPD health states 3 Long-run clinical and economic consequences of oral steroids 4 Comparison of effectiveness vs. efficacy in asthma/COPD models 5 Validating long-term outcomes predicted by models vs. real-life data 6 Rare disease modelling 7 Cost-effectiveness of new technologies in asthma/COPD 8 Development of respiratory disease specific CEA guidelines Other ideas?
  11. 11. Solving the Puzzle • Marrying high-impact research with funding and expertise o Respiratory CEA gaps identified o Respiratory CEA expertise identified o Funding welcomed – CEA working group is seeking pilot funding routed through REG
  12. 12. Active research seeking funding • PharmacoEconomics journal has requested a review of the value of approved and emerging asthma biologics (Dr. McQueen is leading this effort) o Aim of paper is to systematically review economic data on biologic treatments for asthma and to provide critical insight into key drivers of cost-effectiveness o This effort could be organized through the REG CEA Working group o We are seeking a funding collaborator for this research – Robert.McQueen@ucdenver.edu
  13. 13. Any other business? Contact us for new REG studies: • USA: Jon D Campbell (jon.campbell@ucdenver.edu) • Europe: Job FM van Boven (j.f.m.van.boven@rug.nl)

×